Hepatic cytochrome P-4503A (CYP3A) activity in the elderly

https://doi.org/10.1016/0047-6374(92)90106-NGet rights and content

Abstract

Elderly patients exhibit decreased clearance of multiple drugs biotransformed by the hepatic cytochromes P-450. The cytochromes P-450 are a superfamily of enzymes, which comprise a central component of phase I drug metabolism. Distinct isoforms metabolize specific drugs. In human liver microsomes, the glucocorticoid-inducible cytochrome P-450IIIA, CYP3A, catalyzes the N-demethylation of erythromycin. To examine the activity of hepatic CYP3A in elderly males and females, erythromycin N-demethylation was examined, as reflected by the recently described [14C]erythromycin breath test in 24 healthy volunteers, age 70–88. The [14C]erythromycin breath test was measured in normal elderly males and females to: (a) determine persistence of the gender-related dimorphism (evident in younger subjects) of CYP3A activity in the elderly population, (b) examine the effect of % ideal body weight, age, diet, and medication use on the activity of human hepatic CYP3A, and (c) compare breath test results obtained in normal geriatric volunteers with published results obtained in younger subjects, to determine aging-related alteractions in CYP3A enzyme activity. Erythromycin N-demethylation varied fivefold among these patients. Similar to earlier studies examining erythromycin N-demethylation in younger subjects, CYP3A activity was found to vary with gender in the geriatric cohort. [14C]Erythromycin N-demethylation at 60 min was 3.14% ± 0.75 (n = 13) in females and 2.15% ± 0.77 (n = 11) in males (P = 0.005). In evaluating the role of % ideal body weight and % dietary fat using multivariable linear regression analyses. [14C]erythromycin N-demethylation, was found to decline significantly as % ideal body weight increased (P = 0.001). This was not confounded by gender. [14C]Erythromycin N-demethylation was not related to dietary fat intake (P < 0.13). [14C]Erythromycin N-demethylation in the elderly volunteers was similar to values reported for subjects aged 20–60. Performance of a new non-invasive test of the human hepatic glucocorticoid-inducible CYP3A in a geriatric cohort suggests that: (a) the gender-related heterogeneity in function of the glucocorticoid inducible human CYP3A persists during normal aging, (b) that the activity of CYP3A may decrease in obesity, and (c) that the activity of CYP3A is stable throughout normal aging.

References (41)

  • D.E. Salazar et al.

    Obesity as a risk factor for drug-induced organ injury. VI. Increased hepatic P-450 concentration and microsomal ethanol oxidizing activity in the obese overfed rat

    Biochem. Biophys. Res. Comm.

    (1988)
  • M.G. Ladona et al.

    Human fetal and adult liver metabolism of ethylmorphine

    Biochem. Pharmacol.

    (1989)
  • C.M. Hunt et al.

    Effect of normal aging on the activity of human hepatic cytochrome P-450IIE1

    Biochem. Pharm.

    (1990)
  • D.J. Greenblatt et al.

    Drug disposition in old age

    New Engl. J. Med.

    (1982)
  • R.F. Vestal

    Pharmacology and aging

    J. Am. Geriatr. Soc.

    (1982)
  • M.S. Anderson et al.

    American Medical Association White Paper on Elderly Health; Report of the Council on Scientific Affairs

    Arch. Int. Med.

    (1990)
  • D.J. Greenblatt et al.

    Pharmacokinetic aspects of drug therapy in the elderly

    Ther. Drug Monitoring

    (1986)
  • D.R. Abernethy et al.

    Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients

    Ann. Int. Med.

    (1986)
  • J.W. Dundee et al.

    The influence of age on the onset of anaesthesia with midazolam

    Anaesthesia

    (1985)
  • D.J. Greenblatt et al.

    Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity

    J. Pharm. Exp. Ther.

    (1982)
  • Cited by (84)

    • Dietary-Induced Obesity, Hepatic Cytochrome P450, and Lidocaine Metabolism: Comparative Effects of High-Fat Diets in Mice and Rats and Reversibility of Effects With Normalization of Diet

      2020, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      In people with nonalcoholic fatty liver disease (NAFLD), a condition associated with obesity, significant reductions were observed in the protein expression of CYP3A4 in the liver.35,36 The metabolism of certain drugs primarily metabolized by CYP3A4 was significantly reduced in obese patients compared to healthy subjects.7,37,38 Similar findings were observed in hepatocytes from patients with NAFLD, who had reduced expression levels of a number of drug metabolizing enzymes including CYP3A4, 1A2, and 2C isoforms.39

    • Physiologically based pharmacokinetic modelling to guide drug delivery in older people

      2018, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Blanco et al. [32] investigated age related changes in microsomal CYP1A2 (ethoxyresorufin), CYP2E1 (ethoxycoumarin), CYP3A4/5 (midazolam) and CYP2C8 (paclitaxel 17α position) and found no age related change in activity between subjects >60 years compared to those >10 to 59 years. Previously Hunt et al. had also demonstrated no change in CYP3A activity in vitro with age (range 27 to 83 years) [33] and also in vivo using the erythromycin breath test between an older (70 to 88 years) compared to a younger age group (20 to 60 years) [34]. In another study the same authors showed no change in CYP2E1 activity over the range of 30 to 75 years [35].

    View all citing articles on Scopus
    View full text